^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Cholangiocarcinoma

    Related cancers:
    1d
    Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function (clinicaltrials.gov)
    P1, N=36, Terminated, M.D. Anderson Cancer Center | Trial completion date: Apr 2028 --> Jun 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2028 --> Jun 2026; < 75% participation
    Trial completion date • Trial termination • Trial primary completion date
    1d
    ACADEMY: A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC (clinicaltrials.gov)
    P2, N=38, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Trial completion date: Oct 2027 --> Oct 2028 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    AiTan (rivoceranib) • AiRuiLi (adebrelimab)
    1d
    STU-2022-1076: Domvanalimab and Zimberelimab in Advanced Liver Cancers (clinicaltrials.gov)
    P2, N=58, Active, not recruiting, University of Texas Southwestern Medical Center | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date • Pan tumor
    |
    Yutuo (zimberelimab) • domvanalimab (AB154)
    1d
    TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE) (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, Case Comprehensive Cancer Center
    New trial
    1d
    AFPᶜ³³²T in Advanced HCC (clinicaltrials.gov)
    P1, N=39, Completed, Adaptimmune | Active, not recruiting --> Completed
    Trial completion
    |
    AFP (Alpha-fetoprotein)
    |
    ADP-A2AFP
    1d
    Carcinogenic role of ESCO2 in cholangiocarcinoma: integration of bioinformatics analysis and experimental validation. (PubMed, Transl Cancer Res)
    In vivo experiments confirmed that ESCO2 promotes tumor growth and shortens survival in mice. ESCO2 is a key regulatory gene affecting the development of CCA and plays an important role in CCA cell proliferation, which could be a new target for CCA diagnosis and treatment.
    Journal
    |
    CD8 (cluster of differentiation 8) • ESCO2 (Establishment Of Sister Chromatid Cohesion N-Acetyltransferase 2)
    1d
    Epithelial cell expansion drives cyst progression in genetic models of autosomal recessive polycystic kidney disease. (PubMed, iScience)
    Pharmacological CDK1 inhibition attenuated fibrocystic liver disease in vivo. These findings show that epithelial cell expansion is the primary driver of cystogenesis and loss of fibrocystin activates a pro-proliferative program that can be therapeutically targeted.
    Journal
    |
    CDK1 (Cyclin-dependent kinase 1) • PKHD1 (PKHD1 Ciliary IPT Domain Containing Fibrocystin/Polyductin)
    1d
    SIAG-BTC: Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC. (clinicaltrials.gov)
    P2, N=107, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Yervoy (ipilimumab) • gemcitabine • Tyvyt (sintilimab) • albumin-bound paclitaxel
    2d
    A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, Ruijin Hospital
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1)
    |
    KRAS mutation • NRAS mutation • RAS mutation • HRAS mutation • KRAS G12 • NRAS G12
    2d
    Cholangiocarcinoma in the Era of Precision Medicine: Emerging Insights and Therapeutic Strategies. (PubMed, Curr Pharm Des)
    Advances in molecular profiling and immunotherapy are reshaping the management of cholangiocarcinoma, enabling more personalized treatment strategies. Continued integration of precision oncology into clinical practice and prospective trials will be critical to improving outcomes for cholangiocarcinoma moving forward.
    Journal
    |
    MSI (Microsatellite instability) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • FGFR (Fibroblast Growth Factor Receptor)
    |
    cisplatin • gemcitabine • capecitabine
    2d
    Analysis and validation of abnormal signaling pathways and immune cell infiltration characteristics in digestive system cancers based on peroxisome-related genes. (PubMed, Biol Direct)
    Peroxisomes act as pivotal regulators of digestive cancer progression by modulating signaling pathways, the TIME, therapeutic resistance, and lipid metabolism. Targeting peroxisomal function, particularly in high-risk subgroups of HCC and CRC, warrants further exploration as a promising therapeutic strategy.
    Journal
    |
    PEX13 (Peroxisomal Biogenesis Factor 13)
    |
    Lenvima (lenvatinib)
    2d
    Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase II (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, HuiKai Li
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)